Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Leukemia, Myeloid, Acute 24Breast Neoplasms 15Sarcoma 9Myelodysplastic Syndromes 9Carcinoma, Non-Small-Cell Lung 9Stomach Neoplasms 8Multiple Myeloma 7Leukemia, Myelomonocytic, Chronic 7Myeloproliferative Disorders 6Uterine Cervical Neoplasms 5Lymphoma, Large B-Cell, Diffuse 5Recurrence 4Prostatic Neoplasms 4Neoplasms 4Melanoma 4Lung Neoplasms 4Leukemia, Monocytic, Acute 4Head and Neck Neoplasms 4Carcinoma, Hepatocellular 4Biliary Tract Neoplasms 4Advanced Solid Tumour 4Stomatitis 3Squamous Cell Carcinoma of Head and Neck 3Ovarian Neoplasms 3Neuroendocrine Tumors 3Mucositis 3Leukemia, Myelomonocytic, Acute 3Esophageal Squamous Cell Carcinoma 3Esophageal Neoplasms 3Cholangiocarcinoma 3

Interventions

Octreotide 3Capecitabine 3Temozolomide 2Everolimus 2Bortezomib 2vatalanib 1romidepsin 1regorafenib 1pazopanib 1pasireotide 1motesanib diphosphate 1fluorodopa F 18 1batifiban 1Thalidomide 1Streptozocin 1Sorafenib 1Solutions 1Saline Solution 1Panobinostat 1Melphalan 1Leucovorin 1Irinotecan 1Injections 1Gefitinib 1Fluorouracil 1Cisplatin 1Biological Therapy 1Bevacizumab 14-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 1177Lu-octreotide, DOTA(0)-Tyr(3)- 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Insulinoma × Injections × Clear all
NCT03053284 2021-05-14

Pasireotide in Hyperinsulinemic Hypoglycemia

Montefiore Medical Center

Phase 2 Withdrawn
Endocrine

Hyperinsulinism, Insulinoma, Congenital Hyperinsulinism

Data powered by HemOnc (CC BY 4.0) Colophon âš¡